A Phase 1b Study of CLN-619 in People With Multiple Myeloma

Full Title

A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (anti-MICA/MICB Antibody) in Patients with Relapsed and Refractory Multiple Myeloma

Purpose

Researchers are finding the best dose of CLN-619 to treat multiple myeloma. The people in this study have multiple myeloma that has come back or keeps growing after treatment.

CLN-619 targets and blocks a protein in the body that can cause tumors to grow. This selective targeting may help protect healthy cells from damage. CLN-619 is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have multiple myeloma that has come back or keeps growing after treatment.
• Have recovered from the serious side effects of prior therapies before getting CLN-619.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Sridevi Rajeeve’s office at 646-608-4310.